Nuwellis (NASDAQ:NUWE) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Earnings & Valuation
This table compares Nuwellis and Vaso’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nuwellis||$7.44 million||2.75||-$15.84 million||($10.67)||-0.19|
This table compares Nuwellis and Vaso’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Nuwellis and Vaso, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Nuwellis currently has a consensus price target of $9.00, suggesting a potential upside of 341.18%. Given Nuwellis’ higher possible upside, equities analysts plainly believe Nuwellis is more favorable than Vaso.
Volatility & Risk
Nuwellis has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Vaso has a beta of 3.24, suggesting that its share price is 224% more volatile than the S&P 500.
Insider & Institutional Ownership
10.1% of Nuwellis shares are held by institutional investors. Comparatively, 0.0% of Vaso shares are held by institutional investors. 0.4% of Nuwellis shares are held by insiders. Comparatively, 44.6% of Vaso shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Vaso beats Nuwellis on 8 of the 12 factors compared between the two stocks.
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm’s products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment provides Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease, as well as in-service training support. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. The company was incorporated in 1987 and is headquartered in Plainview, New York.
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.